Copy to clipboard 
Tetrous was issued US Patent No. 12,115,279, specifically related to the EnFix family of demineralized cortical bone fiber implants and their method of manufacture. This is the company’s fourth patent for the EnFix line.
EnFix allograft products are designed to enhance healing at the tendon-to-bone interface, i.e., at the enthesis, where failure often occurs. The 100% demineralized bone fiber (DBF) implants provide osteoinductivity and osteoconductivity, while FormLok technology imparts shape retention to the device, even in the wet environment of arthroscopic surgery. Optimal biologic performance is provided in an implant that has minimal disruption to the current surgical technique.
The newly issued patent, titled “Demineralized Bone Fiber Implant Compositions and Methods for Rotator Cuff and ACL Repair,” further augments Tetrous’ portfolio of intellectual property covering demineralized cortical bone fiber implants, bone healing and enhancement of tendon to bone repair.
More than 700 EnFix RC and EnFix TAC implants have been implanted in the US and Australia since July 2023. Follow-up MRIs on patients at six months post-surgery consistently show reformation of the enthesis, thickening of the tendon and little to no edema. While the majority of the procedures have been for rotator cuff, the technology is slated for additional applications in hip, biceps, Achilles and ACL procedures.
“We are pleased that the U.S. Patent Office has yet again recognized the uniqueness of our technology and has granted this additional patent,” said Andy Carter, PhD, Tetrous’ Co-Founder, Director and co-inventor on the issued patent. “Our growing intellectual property portfolio provides Tetrous a sustainable competitive advantage in the enthesis repair market.”
Source: Tetrous, Inc.
Tetrous was issued US Patent No. 12,115,279, specifically related to the EnFix family of demineralized cortical bone fiber implants and their method of manufacture. This is the company's fourth patent for the EnFix line.
EnFix allograft products are designed to enhance healing at the tendon-to-bone interface, i.e., at the enthesis, where...
Tetrous was issued US Patent No. 12,115,279, specifically related to the EnFix family of demineralized cortical bone fiber implants and their method of manufacture. This is the company’s fourth patent for the EnFix line.
EnFix allograft products are designed to enhance healing at the tendon-to-bone interface, i.e., at the enthesis, where failure often occurs. The 100% demineralized bone fiber (DBF) implants provide osteoinductivity and osteoconductivity, while FormLok technology imparts shape retention to the device, even in the wet environment of arthroscopic surgery. Optimal biologic performance is provided in an implant that has minimal disruption to the current surgical technique.
The newly issued patent, titled “Demineralized Bone Fiber Implant Compositions and Methods for Rotator Cuff and ACL Repair,” further augments Tetrous’ portfolio of intellectual property covering demineralized cortical bone fiber implants, bone healing and enhancement of tendon to bone repair.
More than 700 EnFix RC and EnFix TAC implants have been implanted in the US and Australia since July 2023. Follow-up MRIs on patients at six months post-surgery consistently show reformation of the enthesis, thickening of the tendon and little to no edema. While the majority of the procedures have been for rotator cuff, the technology is slated for additional applications in hip, biceps, Achilles and ACL procedures.
“We are pleased that the U.S. Patent Office has yet again recognized the uniqueness of our technology and has granted this additional patent,” said Andy Carter, PhD, Tetrous’ Co-Founder, Director and co-inventor on the issued patent. “Our growing intellectual property portfolio provides Tetrous a sustainable competitive advantage in the enthesis repair market.”
Source: Tetrous, Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
